SymbioTec signs representation contract with Tytonis

05-Mar-2009 - Germany

SymbioTec GmbH and Tytonis B.V. announced that they have signed a representation contract under which Tytonis will support SymbioTec in its ongoing financing round and also to support the Company in the out-licensing of its lead clinical product ONCOHIST™, for the treatment of various cancers. The undisclosed contract contains a risk sharing provision under which Tytonis participates in the commercial risk involved with the product transaction process.

ONCOHIST™ is an endogenous protein derived from the histone family. Prof. Zeppezauer’s group has found that it has remarkable antibacterial and oncolytic properties due to its particular structure and the presence of cationic properties. This is corroborated by its high presence in the small intestine where, in comparison to the colon region, almost no bacteria and only small incidence of cancer occur. The mechanism of action is related to its ability to bind to particular anionic charged phospholipids and other histone components. These only appear on the surface of irregular and fast growing tumor cells. Due to subsequent cell-lysis and apoptosis the cancer cells are killed without affecting other healthy cells and tissues in the body.

Applying ONCOHIST™ to all major known human-derived cancer cell lines demonstrated complete, effective eradication of the tumor cells in vitro. This was latterly confirmed in animal studies. Signs of efficacy were also noted in a recently concluded clinical phase Ib/IIa dose finding trial with 22 AML (Leukemia) patients. The ONCOHIST™ compound formulation showed no significant immunological and toxicological effects in either animals or humans. This may be explained by the fact that histones are genetically highly conserved endogenous proteins. The different mode of action of ONCOHIST™together with its high tolerability would make the compound highly interesting for combination therapies with other oncolytic drugs. ONCOHIST™ is protected by 10 patent families until 2028, of which 40 patents are already granted.

https://www.bionity.com/en/news/97765/symbiotec-signs-representation-contract-with-tytonis.html